1. Liquid biopsy - emergence of a new era in personalized cancer care
   Jessy Abraham et al, 2018, Appl Cancer Res CrossRef
2. Extracellular vesicles and ctDNA in lung cancer: biomarker sources and therapeutic applications
   Chengliang Huang et al, 2018, Cancer Chemother Pharmacol CrossRef
3. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction
   Laura S. Hiemcke-Jiwa et al, 2018, JAMA Ophthalmol CrossRef
4. Technical considerations for circulating tumor DNA detection in oncology
   Claire Franczak et al, 2019, Expert Review of Molecular Diagnostics CrossRef
5. Concordance of changes in the extracellular DNA of blood plasma and DNA of tumor tissue using the example of EGFR gene mutations in patients with non-small cell lung cancer
   A. A. Gneusheva et al, 2018, Lab. sluzh. CrossRef
6. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
   Jatta Saarenheimo et al, 2019, Front. Oncol. CrossRef
7. Diagnostic and prognostic impact of cell-free DNA in human cancers: systematic review
   Klara Cervena et al, 2019, Mutation Research/Reviews in Mutation Research CrossRef
8. null
   Pauline Gilson, 2020 CrossRef
9. Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study
   Zhengquan Yang et al, 2019, Targ Oncol CrossRef
10. Diagnostic test accuracy of droplet digital PCR for the detection of EGFR mutation (T790M) in plasma: systematic review and meta-analysis
    Yingyin Liao et al, 2019, Clinica Chimica Acta CrossRef
11. Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients
    Leila Jahangiri et al, 2019, Cancers CrossRef
12. Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis
    Caichen Li et al, 2020, Front. Oncol. CrossRef
13. Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA.
    Masaki Hanibuchi et al, 2019, Oncotarget CrossRef
14. The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review
    Frederik van Delft et al, 2020, Cancers CrossRef
15. A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations.
    Christina Demuth et al, 2018, Oncotarget CrossRef
16. Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay
    Xiang Song et al, 2020, Br J Cancer CrossRef
17. Validation of a One-Step Reverse Transcription-Droplet Digital PCR (RT-ddPCR) Approach to Detect and Quantify SARS-CoV-2 RNA in Nasopharyngeal Swabs
    Catia Mio et al, 2021, Disease Markers CrossRef
18. Cell-free Nucleic Acids in Cancer
    Liron Barnea Slonim et al, 2021, Advances in Molecular Pathology CrossRef
19. Challenges in promoter methylation analysis in the new era of translational oncology: A focus on liquid biopsy
    Catia Mio et al, 2022, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease CrossRef
20. Cell-free Nucleic Acids in Cancer
    Liron Barnea Slonim et al, 2022, Clinics in Laboratory Medicine CrossRef
21. ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA
    Nicola Casiraghi et al, 2020 CrossRef
22. Development of multiplex drop-off digital PCR assays for hotspot mutation detection of KRAS, NRAS, BRAF and PIK3CA in the plasma of colorectal cancer patients
    Qian Yu et al, 2023, The Journal of Molecular Diagnostics CrossRef